NYSE
20.72USD
+0.39 (+1.92%)
We have scored 37 news catalysts on Healthpeak Properties, Inc. (DOC) over the past 12 months. The biggest single-day move next to one of them came Oct 12, 2025, when DOC closed −2.2%: “Buy Any Of 14 IDEAL 'Safer' S&P 500 October Dividend Dogs”. Coverage across the window leans positive (average ticker sentiment +0.58). Most of the impact sits in sector realestate and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
14.3B
P/E
—
EPS
—
Beta
0.99
52W range
15.7-22.95
Day range
20.38–20.72
Open
20.44
Prev close
20.33
Volume
6.1M
Avg volume
6.7M
Dividend
1.22
IPO
1985-05-23
Analysts publish price targets on DOC, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
10 analyst price targets from $19 to $24
as of 2026-09-06
The market is 8% below the median target — more cautious than the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Healthpeak Properties, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for DOC: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Healthpeak Properties, Inc. is an S&P 500 constituent operating as a fully integrated real estate investment trust (REIT). The firm is dedicated to the acquisition, management, and development of premier properties essential for both medical research and the provision of healthcare services.
The price sits at the 20th percentile of published models, leaning bearish by declining to pay for the 16% upside that the three bull-case banks require.
What the disagreement turns on
Whether the lab segment's occupancy can recover to at least 78.5% and deliver positive same-store NOI growth, which the price currently discounts; unit_volumes can measure this, but pricing and location-level leasing spreads cannot be tested here.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
